Suzzallo Library reading room with long study tables and bookshelves

Kratom Research Sources: Books, Databases, Agencies, and Organizations

Sources reviewed: July 15, 2026. Database coverage, trial records, agency positions, organizational roles, and linked documents can change; the date attached to each record remains part of the evidence.

Kratom research concerns a plant that people consume for effects. In Southeast Asian records, people chew fresh leaves or drink water-based preparations for alertness, energy, endurance, pain relief, relaxation, social use, or managing withdrawal. Modern products also include powder, capsules, tablets, gummies, liquids, and concentrated extracts. Human studies and surveillance reports describe desired effects alongside nausea, dizziness, constipation, sweating, sedation, dependence, withdrawal, interactions, and other risks.

No single website can answer every question about that human reality. Botanical databases establish names and distribution records. Literature databases locate papers. Trial registries show what investigators registered. Agencies publish assessments and actions. Advocacy and trade organizations publish positions, programs, and sponsored work. The most reliable route is to use each source for the job it actually performs.

Match the source to the question

  • What is the accepted plant and where is it native? Start with Royal Botanic Gardens, Kew and other botanical data systems.
  • What human, chemical, or pharmacological studies have been published? Use PubMed, then open the complete paper through PubMed Central or the publisher.
  • What human studies were registered, completed, or posted with tabular findings? Check ClinicalTrials.gov and compare the registry entry with later publications.
  • What did WHO, FDA, or DEA state or do? Open the dated agency record, then distinguish an assessment, announcement, guidance document, warning letter, notice, and operative rule.
  • What position is an advocacy or trade group taking? Read the organization’s own document as a primary record of its position, with its mission, membership, funding, and sponsor role visible.

The kratom information-evaluation guide provides a claim-by-claim review method. The resource map here identifies where to obtain the underlying records, while the kratom glossary defines the botany, testing, label, and human-research terms used in them.

Plants of the World Online: accepted identity and native range

Plants of the World Online (POWO), maintained by Royal Botanic Gardens, Kew, records Mitragyna speciosa as an accepted species in the coffee family, Rubiaceae. Its entry includes synonyms, classification, cited taxonomic authorities, and a native range extending from southern Indochina to New Guinea.

POWO is the strongest starting point for the currently accepted species name and broad botanical range. It cannot establish where a commercial pouch was grown, whether its contents are authentic, or what alkaloid concentration a lot contains. Those questions require supply-chain records, botanical identity work, and chemical analysis. The botanical guide to the kratom tree connects the database entry to physical plant features and habitat evidence.

IPNI: the publication history behind a plant name

The International Plant Names Index (IPNI) records nomenclatural details such as the author abbreviation, original publication, collation, and a stable Life Sciences Identifier. This is useful when older literature uses Mitragyna speciosa with different author citations or synonyms.

IPNI is a nomenclatural database rather than a final ruling on which name taxonomists currently accept. That distinction is why IPNI links outward to taxonomic opinions such as POWO. A publication record for a name and current acceptance of a species are related questions, not the same field.

GBIF: occurrence records and their limits

The Global Biodiversity Information Facility (GBIF) aggregates species and occurrence data from museums, herbaria, universities, government bodies, citizen-science programs, and other publishers. A Mitragyna speciosa record can lead to specimen or observation data with location, date, collection, and publishing-dataset information.

Occurrence points require inspection. Coordinates can be generalized, historical labels can be imprecise, records can be duplicated, and a plotted point does not prove present abundance. GBIF is valuable for finding the contributing specimen or dataset; the publisher, collection method, identification, coordinates, and license remain attached to the record.

PubChem: compound identity, not package composition

PubChem, operated by the National Library of Medicine, links chemical names, structures, identifiers, deposited bioassay information, safety records, and literature for compounds such as mitragynine. It is especially useful when one compound appears under several synonyms or when a paper supplies only an identifier.

A PubChem entry describes a chemical entity and the data linked to it. It does not show that a tablet, extract, or leaf lot contains that compound at the amount printed on a label. Product composition belongs to the actual sample, analytical method, units, and batch record. The kratom alkaloid guide connects mitragynine and 7-hydroxymitragynine records to plant, metabolism, receptor, and human evidence.

PubMed: the main index for biomedical literature

PubMed is maintained by the National Center for Biotechnology Information at the U.S. National Library of Medicine. It indexes citations and abstracts from MEDLINE, PubMed Central, and selected NCBI Bookshelf content. Useful query terms include kratom, Mitragyna speciosa, mitragynine, and 7-hydroxymitragynine, combined with the population or outcome of interest.

A PubMed record can expose the paper’s authors, journal, publication type, abstract, PMID, MeSH terms, funding information, related citations, and full-text links. Inclusion is not an endorsement of the conclusion. PubMed contains original studies, reviews, case reports, letters, editorials, and other publication types, so the complete paper and its design still determine what the citation supports.

PubMed Central: free full text with version labels

PubMed Central (PMC) is the National Library of Medicine’s free full-text archive for biomedical and life-science literature. It can contain the journal version, a peer-reviewed author manuscript, or a clearly identified preprint. The PMCID gives an archived record a stable identifier.

Free full text is access, not a universal quality grade. Check the version banner, journal, dates, corrections, funding, conflicts, methods, and supplementary files. When PMC hosts an author manuscript, the publisher’s version may contain final pagination or copy edits. When it hosts a preprint, peer review has not yet occurred.

ClinicalTrials.gov: registered human studies

ClinicalTrials.gov is operated by the National Library of Medicine for information submitted by study sponsors and investigators. Kratom-related records may identify the intervention, study material, sponsor, enrollment, eligibility criteria, locations, outcome measures, status, completion dates, posted findings, and linked publications.

Registration shows that a study record exists; it does not mean the U.S. government approved the study’s safety or scientific conclusion. ClinicalTrials.gov states that sponsors and investigators are responsible for the submitted information and that the government does not review or approve all listed studies. Compare the registered primary outcomes with the eventual paper, and note whether a completed record has posted findings or only a protocol summary.

Books and monographs: deep context with a publication cutoff

Robert B. Raffa’s edited volume Kratom and Other Mitragynines, published by CRC Press with a 2015 copyright, collects chapters on botany, chemistry, analytical detection, metabolism, pharmacology, toxicology, epidemiology, and legal status. It remains a useful map of earlier literature and specialist terminology.

Its cutoff is also important. Controlled human studies, market changes, analytical methods, agency actions, and the 7-OH product market developed substantially after the book was assembled. Use a monograph for synthesis and historical references, then follow its citations forward in PubMed.

  • NLM Catalog: bibliographic records for books, journals, electronic resources, and other materials in National Library of Medicine collections.
  • NCBI Bookshelf: free full text for selected biomedical books, reports, systematic reviews, guidelines, and reference works.
  • WorldCat: a global library catalog useful for locating editions, print holdings, dissertations, and older works that may not appear in a biomedical index.

WHO: international review records

The World Health Organization’s Expert Committee on Drug Dependence assembled a 2021 pre-review report on kratom, mitragynine, and 7-hydroxymitragynine. The 44th ECDD document collection also preserves questionnaires, committee materials, and related records. The committee’s summary stated that evidence was insufficient to recommend a critical review at that time and recommended continued WHO surveillance.

These documents are primary sources for what the committee reviewed and recommended in 2021. They are not a permanent verdict on all later evidence, a U.S. product approval, or a statement of current law in every country. WHO assessment dates and meeting numbers should remain visible whenever the recommendation is quoted.

FDA: agency position, research, warnings, and enforcement

The FDA and Kratom hub states the agency’s current U.S. position, describes reported use and adverse events, summarizes FDA research, and links to warning letters, seizures, recalls, import actions, and 7-OH materials. It is the primary source for what FDA states and what FDA has done.

Agency attribution matters. “FDA states” is more accurate than turning an agency assessment into an unattributed law of nature. A warning letter records the agency’s allegations to a named firm at a particular time; a recall notice identifies products and lots; a research page describes agency work. None of those document types substitutes for the complete scientific paper or operative legal text when that is the question.

DEA, the Federal Register, and eCFR: separate summaries from operative records

The DEA kratom fact sheet summarizes the agency’s description of forms, effects, risks, and legal status. DEA announcements and press releases record what the agency announced on a particular date. For the scope and legal status of a scheduling action, open the signed Federal Register notice, check for any later temporary order, and verify the current schedules in 21 CFR part 1308. As checked July 16, 2026, document 2026-13580 remained a notice of intent rather than an effective scheduling order, and the eCFR current through July 14 did not list 7-hydroxymitragynine in part 1308.

The record type prevents major errors. A notice of intent, temporary scheduling order, proposed rule, final rule, press release, and fact sheet have different legal effects. The DEA 7-OH scheduling tracker keeps the named compounds, thresholds, dates, and official documents together without rewriting a 7-OH action as a ban on every natural leaf product.

NIH RePORTER and NCCIH: funding records and public summaries

NIH RePORTER identifies NIH-funded projects, principal investigators, institutions, award years, abstracts, and linked publications when available. It is useful for finding who funded a kratom project and what the award proposed to study. A grant abstract is a plan and funding record, not a completed finding.

The National Center for Complementary and Integrative Health maintains a public kratom overview that summarizes consumption, reported effects, research, and safety concerns for general readers. It can provide orientation, while its linked studies and agency records supply the evidence for a precise claim. The current kratom research synthesis places specific human findings, metabolism, pharmacology, and risks into one dated account.

Advocacy and trade sources need visible role labels

Advocacy and trade organizations can publish valuable policy records, model bills, standards, commissioned analyses, conference materials, public comments, and links to research. Their institutional interest belongs beside the document rather than hidden or treated as automatic disqualification.

American Kratom Association

The American Kratom Association (AKA) identifies itself as a Virginia-registered 501(c)(4) advocacy organization devoted to preserving legal consumer access. Its site is a primary source for AKA’s policy positions, lobbying priorities, consumer statements, and proposed regulatory language. The AKA GMP Standards Program publishes private program criteria and a qualified-vendor process; it is administered by AKA and is not an FDA approval or government certification.

Global Kratom Coalition

The Global Kratom Coalition (GKC) describes itself as an alliance of consumers, experts, and industry leaders that advocates for leaf-kratom access, regulation, education, and research funding. Its materials are primary sources for GKC’s positions and initiatives. For a study hosted, promoted, or funded by GKC, inspect the paper’s authorship, funding statement, material supplier, analysis plan, and conflict disclosure rather than assuming independence from the organization’s mission.

American Herbal Products Association

The American Herbal Products Association (AHPA) identifies itself as the national trade association for the herbal-products industry. AHPA publishes trade requirements, voluntary guidance, committee materials, and regulatory comments. Its 2025 kratom and synthesized-alkaloid guidance reflects the consensus of AHPA members and its board; the document itself says guidance policies are not statutes, regulations, or legal advice.

Funding and conflicts should change scrutiny, not replace it

A government page reflects an agency mandate. An advocacy document advances a mission. A trade-association policy represents industry participants. A university paper can still involve sponsor funding, supplied products, patents, consulting, litigation, or undisclosed assumptions. None of those labels alone establishes whether a specific result is correct.

  • Read author affiliations, funding acknowledgments, and conflict disclosures.
  • Identify who selected or supplied the kratom material and whether its chemistry was measured.
  • Check whether the sponsor designed the study, analyzed data, approved the manuscript, or controlled publication.
  • Look for independent replication and consistency across different materials and research groups.
  • Separate an organization’s policy conclusion from the measurements in a cited paper.

Kratom Paradise sells kratom products, so its educational library also has a commercial context. The editorial standards and sourcing policy describes how sources, corrections, commercial interests, and unsupported claims are handled. Direct links to primary records allow readers to verify the evidence rather than relying on the retailer’s summary alone.

A durable source-check sequence

  1. Write the exact plant, compound, product, population, outcome, jurisdiction, and date in question.
  2. Use POWO or IPNI for name and taxonomy; PubChem for compound identity; PubMed for papers; ClinicalTrials.gov for registrations.
  3. Open the complete paper, protocol, agency notice, or organizational document.
  4. Record the PMID, PMCID, DOI, trial number, docket number, publication date, or stable agency identifier.
  5. Check the material consumed or tested, the measured human effects or risks, the methods, funding, conflicts, and later corrections.
  6. For law or regulation, confirm the operative text and effective date rather than relying on a summary page.
  7. For advocacy or trade material, preserve the organization’s declared mission and sponsor role.

That sequence keeps the human subject visible. “Kratom research” can mean a person chewing fresh leaf in southern Thailand, a participant consuming chemically characterized tea, an assay using purified mitragynine, a survey respondent describing withdrawal, or a laboratory analyzing a commercial tablet. The source is useful when the exact material and question travel with its conclusion.

Sources and further reading

For research-literacy and source-navigation education only. It is not medical or legal advice and does not replace review of the complete source.

Image credit: “Suzzallo Library reading room” by Priyaranjan Pattnayak, CC BY-SA 4.0; cropped from the original.

Written By : Kratom Paradise Editorial Team

Previous Article
Next Article